併購發威保瑞藥業：要做製藥界的台積電記者林淑慧／台北報導 2018年03月29日 保瑞藥業董事長盛保熙今（29）日表示，日前收購美國Nasdaq上市公司Impax旗下益邦製藥100％股權，受惠國際代工挹注，讓保瑞躍升為全台產能前五大的口服製劑藥廠，期許保瑞能成為「製藥界的台積電」。櫃買中心今天舉行生醫產業業績發表會，邀請中天生技、保瑞藥業及健亞公司，向法人及投資大眾報告近期業績及今年度的營運展望。「要讓全世界能用到台灣做的藥，」盛保熙表示，收購Impax旗下益邦製藥，不僅獲Impax藥品銷美訂單與帕金森氏症用藥在台經銷權，取得全廠USFDA/MHRA合格銷美資格，有助保瑞後續的國際佈局。去年十月，Impax與Amneal合併，基於海外經營策略調整，加上成本上漲壓力，才決議出售斥資40億元興建的益邦製藥廠，而保瑞以成為Impax的合作夥伴為訴求，並以最低出資價格得標，將共創雙贏契機。保瑞指出，口服製劑產能躍進，有助爭取CMO/CDMO的代工訂單；由於訂單掌握度高，加上國際代工訂單可望成長，已規劃在今年增加2條液劑產線，而併購後的淨利率有機會不亞於原事業群水準，年營收可望逾倍跳增。針對併購後的挑戰，盛保熙認為在於台美文化差異，為消弭員工疑慮及提升信心，他花了二、三個月時間，每周到該廠三次，與美籍員工面對面溝通保瑞的國際佈局計劃及願景，期許保瑞能成為藥業市場中的台積電，協助生技產業打進國際。
Impax Shareholders Approve Proposed Business Combination with Amneal Mar 27, 2018 BRIDGEWATER, N.J., March 27, 2018 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that at its special meeting of stockholders held today, Impax stockholders overwhelmingly approved the previously announced business combination of Impax with Amneal Pharmaceuticals LLC. At the meeting, 51.8 million shares, or approximately 99% of votes cast, voted in favor of the business combination. "We appreciate the strong support we have received from Impax shareholders for our transformational combination with Amneal," said Paul Bisaro, President and Chief Executive Officer of Impax. "Today's approval represents an important milestone in the process to combine our two organizations and create a diversified pharmaceutical company with stronger capabilities and greater resources. We look forward to continuing to work closely with Amneal to complete the transaction so we can provide greater access to safe and affordable medicine for patients, open up new opportunities for our employees and deliver enhanced value for shareholders." Impax's shareholder approval satisfies one of the conditions to the closing of the transaction. The closing of the transaction remains subject to certain regulatory approvals and satisfaction of customary closing conditions, and is expected to occur in the second quarter of this year.
About Amneal Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in its operations in North America, Asia, and Europe, working together to bring high-quality, affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. For more information, visit www.amneal.com.
About Impax Impax Laboratories, Inc. is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments. For more information, please visit Impax's web site at: www.impaxlabs.com.
No comments:
Post a Comment